drugset / Trial / NCT06643819
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
RandomizedParallel-groupDouble-blindTreatment
Summary
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)
Timeline
- Start
- 2024-10-14
- Primary completion
- 2026-03-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacubitril-Valsartan | Unknown | 100 mg | Oral |
| Subject | Sacubitril-Valsartan | Unknown | 200 mg | Oral |
| Subject | Valsartan | Small molecule | 80 mg | Oral |
| Subject | Valsartan | Small molecule | 160 mg | Oral |